The DEA’s Potential Rescheduling of Marijuana (which is definitely a psychedelic)
The U.S. Drug Enforcement Administration (DEA) is reviewing marijuana’s classification under the Controlled Substances Act following a recommendation by Health and Human Services (HHS). HHS proposed moving marijuana from Schedule I to III which would acknowledge its medical benefits while decreasing federal restrictions and legal consequences associated with research and the legal cases relating to […]
Porta Sophia: Protecting Public Domain Innovation in Psychedelic Science
Porta Sophia is playing an invaluable role in protecting public domain and ethical advancement in psychedelic research and innovation, especially as the popularity of psychedelic therapies increases, increasing the potential for overly broad patents that could prevent access to potentially lifesaving treatments.
What Killed Matthew Perry?
Matthew Perry’s sudden death and subsequent findings by the Los Angeles County Coroner’s Office has caused much debate in medical circles regarding the possible role of ketamine in his passing. Dr. Zaid Fadul, an addiction medicine expert and Chief Medical Officer of leading ketamine therapy provider BetterU, during a recent interview with TMZ refuted the […]
Impact of Matthew Perry’s Death on Public Health Policy
Matthew Perry’s death has shed new light on ketamine’s use and regulation for mental health treatments, specifically severe depression treatment. Though ketamine has recently become more accepted among providers for treating depression, incidents like Perry’s can greatly impact public perception and policy-making within health care. Ketamine in the MarketKetamine was initially developed for anesthesia use; […]
MAPS Submits Historic New Drug Application for MDMA-Assisted Therapy of PTSD
MAPS Public Benefit Corporation (MAPS PBC), in a groundbreaking move for psychedelic-assisted therapy, announced their submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration for use of MDMA (midomafetamine capsules) for treating post-traumatic stress disorder (PTSD). This NDA marks a first of its kind submission from any psychedelic-assisted therapy and […]
Recent US policy developments in psychedelics
Recent policy developments and advances in psychedelic research demonstrate a fundamental change in perception and regulation of these substances in the United States: Massachusetts Ballot Initiative for Psychedelic Legalization: Massachusetts is currently considering a ballot initiative from New Approach PAC aimed at legalizing psychedelics through 2024 ballot measure. If passed, this initiative would create a […]
US Veteran’s Administration open to exploring psychedelics to treat PTSD
Since recently, an increasing number of military veterans have turned to psychedelic therapy as an unconventional treatment for post-traumatic stress disorder (PTSD). While this unconventional approach has caused both hope and controversy in the medical community, John Lewandowski of local military veteran fame describes his personal journey using psychedelics to regain his life after struggling […]
Members of European Parliament Advocate EU Support Research into Psychedelic Drugs for Treating Mental Health Disorders
Recently, there has been an surge of advocacy surrounding psychedelic therapies as potential breakthroughs for treating mental health disorders. This movement has now spread into European Parliament where Members of European Parliament (MEPs) are lobbying for increased support and regulatory pathways for psychedelic research. As the European Union considers revising pharmaceutical regulations, MEPs view this […]
The FDA’s Reluctance Toward Ketamine: Ignoring an Opportunity to Address Opioids and Mental Health Crises?
The Food and Drug Administration (FDA) recently released a statement regarding compounded ketamine products used for treating mental disorders. While raising legitimate safety issues associated with such use, they seem to disregard evidence showing its efficacy for treating various psychiatric conditions like depression and anxiety. Given the United States’ ongoing opioid and mental health crises, […]
Exploring California’s New Era for Psychedelics and Cannabis: Examining Assembly Bill 1021 and 623
Recent developments in California’s drug policy represent a major step in revamping society’s perception and handling of psychoactive substances. Governor Gavin Newsom just signed two landmark bills, AB 1021 and 623, that address psychoactive drugs like MDMA and psilocybin as well as cannabis. This article will delve into these laws’ details and repercussions and how […]